Dr. Athanasios Papadopoulos Joins Emergex as Chief Medical Officer

February 27, 2019

OXFORD, England (BUSINESS WIRE) – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the appointment of Athanasios Papadopoulos, MD, as Chief Medical Officer (CMO), effective 1 st March 2019. Dr. Papadopoulos will report directly to Emergex’s CEO Professor Thomas Rademacher.

In his new role Dr. Papadopoulos will use his extensive medical, regulatory and clinical development expertise to provide leadership and direction on the development of Emergex’s growing pipeline of vaccines.

Dr. Papadopoulos joins Emergex from Sanofi, the global pharmaceutical company, where he was most recently Associate Vice President, Senior Director and Clinical Franchise Leader of Global Clinical Sciences since 2015. During his time at Sanofi Dr. Papadopoulos played a critical role in the development of Dengvaxia ®, the first vaccine approved for Dengue fever.

Prior to joining Sanofi, Dr. Papadopoulos worked at Novartis as Medical Affairs Director and Senior Global Clinical Research Physician as well as Lead Head of CLS and Senior Director of Clinical Development. During his time at Novartis, he contributed to the successful development and approval of the breakthrough Bexsero ® Meningitis B vaccine.

Dr. Papadopoulos originally trained as a general practitioner in Greece and specialized as a clinical bio-pathology consultant. He has a wealth of clinical knowledge, strengthened by his more than 20 years of experience working in industry – 10 of which he has spent holding senior life sciences leadership roles.

Dr. Papadopoulos speaks English, French, Italian, Greek and Bulgarian and in his spare time enjoys judo and painting.

Storme Moore-Thornicroft co-founder and COO at Emergex commented, “It is a testament to the quality of our science that someone with Athanasios’ experience has chosen to join our executive management team. His knowledge and experience working in senior positions and the successful development and approval of a number of vaccines makes him the perfect candidate to be our new CMO. We look forward to working with him as our programmes progress into and through clinical development.”

On his appointment as the new CMO, Dr Athanasios Papadopoulos commented, “Coming from a larger, multinational corporation I am eager to explore the opportunities that come with working in a competitive, entrepreneurial, high-growth Company. Emergex’s novel technology and pipeline hold the potential to revolutionise infectious disease prevention and treatment and I am keen to be a part of the team as they strive to realise that vision.”


Notes to Editors

About Emergex Vaccines Holding Limited

Emergex Vaccines Holding Limited (“Emergex”), a UK-based biotechnology company headquartered in Oxford, is pioneering a new approach to vaccine development in order to address some of the world’s most immediate health threats including Flaviviruses, such as Dengue Fever and Zika as well as Filoviruses, such as Ebola and Marburg viruses, and seasonal and pandemic influenza.

The Company has developed a novel and ground-breaking approach to vaccine manufacturing. It utilises 100% synthetic components that have been validated in previous research, to activate T-cells of the immune system to destroy infected human cells. It uses unique technologies together with scientific insights to develop and manufacture vaccines at a fraction of the time and cost of conventional vaccines. These are administered using a skin patch technology which is practical to administer and suited to regions that are infrastructurally-challenged as well as for more advanced regions of the world.

Emergex is initially focussed on creating an internationally accessible, clinical-grade vaccine repository for use by governments, non-governmental organisations and charities, to act as a first line of defence against existing and newly emerging infectious outbreaks.

Emergex is committed to making a positive impact in the communities that are most affected by these infectious outbreaks, where a lack of affordable and effective treatments adversely impacts health and prosperity. Emergex is a member of the Social Stock Exchange in London, the world’s first regulated exchange dedicated to businesses and investors seeking to achieve a positive social and environmental impact through their activities.

Find out more online at www.emergexvaccines.com.


HIMARE - Elected mayor of Himare Fredi Beleri, who remains jailed on remand in a Durres prison since May, said in an interview with SKAI radio on Tuesday that "the rule of law does not function in Albania".

Top Stories


A pregnant woman was driving in the HOV lane near Dallas.

General News

FALMOUTH, MA – The police in Falmouth have identified the victim in an accident involving a car plunging into the ocean on February 20, NBC10 Boston reported.


Echoes of Asia Minor: Life, Catastrophe and Resilience Opens at Consulate in NYC

NEW YORK – Consul General of Greece in New York Dinos Konstantinou in collaboration with the Greek Orthodox Archdiocese of America hosted the opening reception of the moving exhibition Echoes of Asia Minor: Life, Catastrophe and Resilience on November 29 at the Consulate General of Greece in New York.

NEW YORK – The Hellenic Film Society USA presents Maria by Callas, the acclaimed documentary that tells the life story of the legendary Greek-American opera singer.

Enter your email address to subscribe

Provide your email address to subscribe. For e.g. [email protected]

You may unsubscribe at any time using the link in our newsletter.